High risk and reward at KS Biomedix
Article Abstract:
KS Biomedix is a drug developer which has a 70% stake held by Dr Kim TanThe company is developing products to combat arthritis and is in talks with major pharmaceutical concerns. Trials have been encouraging, and there is an anticolon cancer drug scheduled to start trials. Regulatory approval for the rheumatoid drug could mean a 60 million pounds sterling profit for 2002. The company has sound finances and is considering a flotation on Nasdaq to raise further funds.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Biocure: promises to keep
Article Abstract:
Biocure has seen a rise in its share price due to increased enthusiasm for biotechnology shares in the UK. The company is developing products to combat cancer and help cure wounds. Biocure is likely to need more funds for product development and clinical trials may not take place for years. This could mean that investors have to wait some time. The company's share price rise is not justified and investors with shares in Biocure could take a profit.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1996
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Which database, and why. Thurne turns to a packaged solution. Control freak
- Abstracts: 'Franklin and the Green Knight' video launched. WHV promotes 'Cartoon Crack-ups' collection. 'Batman Beyond' promotion launched
- Abstracts: Old lady mugged. Bring on the super police. Europe's 50 financial regulators stifle investors